Abstract
Molecular hybridization is a new concept in drug design and development based on the combination of pharmacophoric moieties of different bioactive substances to produce a new hybrid compound with improved affinity and efficacy, when compared to the parent drugs. Additionally, this strategy can result in compounds presenting modified selectivity profile, different and/or dual modes of action and reduced undesired side effects. So, in this paper, we described several examples of different strategies for drug design, discovery and pharmacomodulation focused on new innovative hybrid compounds presenting analgesic, anti-inflammatory, platelet anti-aggregating, anti-infectious, anticancer, cardio- and neuroactive properties.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Analgesics / chemical synthesis
-
Analgesics / pharmacology
-
Animals
-
Anti-Infective Agents / chemical synthesis
-
Anti-Infective Agents / pharmacology
-
Anti-Inflammatory Agents, Non-Steroidal / chemical synthesis
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / pharmacology
-
Cardiovascular Agents / chemical synthesis
-
Cardiovascular Agents / pharmacology
-
Drug Design*
-
Fibrinolytic Agents / chemical synthesis
-
Fibrinolytic Agents / pharmacology
-
Humans
-
Hypoglycemic Agents / chemical synthesis
-
Hypoglycemic Agents / pharmacology
-
Ligands
Substances
-
Analgesics
-
Anti-Infective Agents
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antineoplastic Agents
-
Cardiovascular Agents
-
Fibrinolytic Agents
-
Hypoglycemic Agents
-
Ligands